{"doi":"10.3389/fimmu.2024.1526563","title":"Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G–seropositive neuromyelitis optica spectrum disorder: a case series report","abstract":"<jats:sec><jats:title>Objectives</jats:title><jats:p>This case series describes adults with aquaporin 4 immunoglobulin G–seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Case information for patients with AQP4-IgG+ NMOSD who received satralizumab for ≥6 months was obtained from US healthcare providers from April 2022 to January 2024. Patient characteristics, examination findings, diagnostic test results, treatment response, and adverse events were recorded.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among the 5 patients (4 women and 1 man) included, ages ranged from 32 to 81 years and 4 patients self-identified as Black/African American and 1 as White. Time since confirmed NMOSD diagnosis ranged from 1 to 14 years. The reasons for initiating satralizumab were route of administration/patient preference (n=3) and inadequate disease control with eculizumab (n=2). The duration of satralizumab treatment was 10 to 31 months. All 5 patients were relapse-free with satralizumab, and adverse events they experienced were primarily asymptomatic laboratory abnormalities.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>In this retrospective case series, satralizumab was effective and well tolerated in patients with NMOSD who switched from eculizumab due to route of administration/patient preference or inadequate disease control. These outcomes align with the long-term efficacy and safety outcomes with satralizumab in the phase 3 SAkura clinical trials.</jats:p></jats:sec>","journal":"Frontiers in Immunology","year":2025,"id":641160,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1666822,"name":"Adnan Subei","orcid":null,"position":1,"is_corresponding":false},{"id":1666823,"name":"Buse Sengul","orcid":null,"position":2,"is_corresponding":false},{"id":519376,"name":"Robert K. Shin","orcid":"0000-0002-1313-8071","position":3,"is_corresponding":false},{"id":1666824,"name":"Paige Goulette","orcid":null,"position":4,"is_corresponding":false},{"id":773017,"name":"Rosemarie Walch","orcid":null,"position":5,"is_corresponding":false},{"id":1666825,"name":"Jeanie Coté","orcid":null,"position":6,"is_corresponding":false},{"id":1666826,"name":"Robert Pace","orcid":null,"position":7,"is_corresponding":false},{"id":530198,"name":"Ahmed Z. Obeidat","orcid":"0000-0002-3549-3277","position":8,"is_corresponding":false},{"id":1666827,"name":"Lisa Ferayorni","orcid":null,"position":9,"is_corresponding":false},{"id":1666828,"name":"Shervin Gholizadeh","orcid":null,"position":10,"is_corresponding":false},{"id":697715,"name":"Hesham Abboud","orcid":"0000-0001-5346-8254","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G–seropositive neuromyelitis optica spectrum disorder: a case series report","abstract":"<jats:sec><jats:title>Objectives</jats:title><jats:p>This case series describes adults with aquaporin 4 immunoglobulin G–seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Case information for patients with AQP4-IgG+ NMOSD who received satralizumab for ≥6 months was obtained from US healthcare providers from April 2022 to January 2024. Patient characteristics, examination findings, diagnostic test results, treatment response, and adverse events were recorded.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among the 5 patients (4 women and 1 man) included, ages ranged from 32 to 81 years and 4 patients self-identified as Black/African American and 1 as White. Time since confirmed NMOSD diagnosis ranged from 1 to 14 years. The reasons for initiating satralizumab were route of administration/patient preference (n=3) and inadequate disease control with eculizumab (n=2). The duration of satralizumab treatment was 10 to 31 months. All 5 patients were relapse-free with satralizumab, and adverse events they experienced were primarily asymptomatic laboratory abnormalities.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>In this retrospective case series, satralizumab was effective and well tolerated in patients with NMOSD who switched from eculizumab due to route of administration/patient preference or inadequate disease control. These outcomes align with the long-term efficacy and safety outcomes with satralizumab in the phase 3 SAkura clinical trials.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39867894","pmcid":"PMC11757099","openalex_id":"https://openalex.org/W4406253990","authors":[],"funders":[],"total_grants":0,"fwci":3.9376,"citation_percentile":0.92626273,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1526563/pdf","host_type":"journal"},{"url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1526563/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fimmu.2024.1526563/full","host_type":"publisher"},{"url":"https://doi.org/10.3389/fimmu.2024.1526563","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39867894","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11757099","host_type":"repository"},{"url":"https://doaj.org/article/ea421bb045a14012b8448d90e08b60f3","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11757099/pdf/fimmu-15-1526563.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11757099","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11757099?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Multiple Sclerosis Research Studies","Peripheral Neuropathies and Disorders","Systemic Lupus Erythematosus Research","Humans","Neuromyelitis Optica","Female","Male","Adult","Antibodies, Monoclonal, Humanized","Aquaporin 4","Middle Aged","Aged","Aged, 80 and over","Immunoglobulin G","Treatment Outcome","Autoantibodies"],"mesh_terms":["Adult","Aged","Aged, 80 and over","Autoantibodies","Female","Humans","Immunoglobulin G","Male","Middle Aged","Neuromyelitis Optica","Treatment Outcome","Aquaporin 4","Antibodies, Monoclonal, Humanized"],"keywords":["Neuromyelitis optica","Eculizumab","Spectrum disorder","Series (stratigraphy)","Medicine","Immunoglobulin G","Antibody","Aquaporin 4","Immunology","Biology","Pathology","Complement system","Psychiatry","AQP4","Case Series","Nmosd","Satralizumab"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T16:17:36.127204Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}